Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jiangsu HengRui Medicine Co., Ltd.
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female patients, 18 years ≤ age ≤ 75 years；
Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1
Histologically confirmed invasive HER2 positive breast cancer.
Known hormone receptor status.
Cardiovascular: Baseline left ventricular ejection fraction (LVEF)≥55% measured by Echocardiogram.
Been treated for early breast cancer with standard of care duration of trastuzumab.
If been not treated neoadjuvantly, lymph node metastases need to be confirmed by postoperative pathology; if been treated neoadjuvantly , have not reached totally pathologic complete response.
Signed informed consent form (ICF) .
You may not be if
Positive clinical and radiologic assessments for local or regional recurrence of disease at the time of study entry.
History of heart disease.
Bilateral breast cancer.
Corrected QT (QTc) interval ≥0.47 seconds.
History of gastrointestinal disease with diarrhea as the major symptom.
Clareo Health | A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
